73% Survival and 56% freedom from HF hospitalization at 2 years1
Kaplan-Meier analysis time to first event ± SE. HF – Heart Failure
Sustained Annular Reduction and TR reduction at 2 years1 (Core lab2)
Nickenig G. et al. Eurointervention 2020 Oct 13:EIJ-D-20-01107. doi: 10,4244/EIJ-D-20-01107
Core Lab - Cardiovascular Research Foundation, New York, NY, USA;
a. Mean, 95% confidence interval. Paired analysis; T-test for continuous variables and Wilcoxon signed-rank test for categorical variables
b. baseline vs. discharge (n=22), baseline vs. one year (n=17) or baseline and two years (n=12).
c. baseline vs. discharge (n=20), baseline vs. one year (n=15) or baseline and two years (n=10).
Sustained Functional Status Improvement at 2 Years
a. Wilcoxon Signed Rank Test, paired analysis comparing baseline vs. 30 days (n=28), baseline vs. 1 year (n=23) or baseline and 2 years (n=17).
b. NYHA – New York Heart Association Functional Classification
Sustained Exercise Capacity and QoL Improvements at 2 Years
a. Paired T-test comparing baseline vs. 30 days (n=23), baseline vs. 1 year (n=19) or baseline and 2 years (n=12)
b. Paired T-test comparing baseline vs. 30 days (n=20), baseline vs. 1 year (n=23) or baseline and 2 years (n=20). 6MWD – six-minute walk distance; KCCQ – Kansas City Cardiomyopathy Questionnaire; QoL – quality of life
Cardioband tricuspid system studies and case presented at the Edwards Lifesciences-sponsored symposium, PCR valves e-course 2020
1 / 1
Register for Cardioband system updates
Receive event and news information from Edwards Lifesciences, including: